Skip to main content

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
Cancel
×
×
Home
  • Home
Chapter
  • Print publication year: 2013
  • Online publication date: February 2015

23 - Aurora kinases in cancer: an opportunity for targeted therapy

from Part 2.1 - Molecular pathways underlying carcinogenesis: signal transduction
Export citation
Summary

The Aurora kinase (AK) family members, Aurora kinase A (AURKA), Aurora kinase B (AURKB), and Aurora kinase C (AURKC) are a collection of highly related and conserved serine/threonine kinases that regulate key cellular functions, mitosis, and multiple signaling pathways. AK dysfunction can cause aneuploidy, mitotic arrest, and cell death. Several studies have reported amplification and/or over-expression of AURKA and AURKB in various human cancers. Additionally, transgenic mouse model studies have established AURKA as a bona fide oncogene. AURKA over-expression in tumors is often associated with gene amplification, genetic instability, dedifferentiated morphology, and poor prognosis. AURKB over-expression is frequently observed in a variety of tumors along with AURKA. AURKB over-expression has also been correlated with increased genetic instability and poor clinical outcome. The function of AURKC in cancer biology is relatively less studied. Given their association with tumorigenesis, both AURKA and AURKB have been targeted for cancer therapy. Currently, a number of selective and non-selective AK inhibitors are being tested in pre-clinical and clinical settings as anti-tumor agents. This chapter reviews the structure, biology and physiological functions of AKs and is an overview of small-molecule modulators of AKs for targeted cancer therapy.

Recommend this book

Email your librarian or administrator to recommend adding this book to your organisation's collection.

Molecular Oncology
  • Online ISBN: 9781139046947
  • Book DOI: https://doi.org/10.1017/CBO9781139046947
Please enter your name
Please enter a valid email address
Who would you like to send this to *

CAPTCHA *

Skip to the audio challenge
×
References
Carmena, M, Earnshaw, WC. The cellular geography of Aurora kinases. Nature Reviews Molecular and Cellular Biology 2003;4:842–54.
Brown, JR, Koretke, KK, Birkeland, ML, Sanseau, P, Patrick, DR. Evolutionary relationships of Aurora kinases: implications for model organism studies and the development of anti-cancer drugs. BMC Evolutionary Biology 2004;4:39.
Kollareddy, M, Dzubak, P, Zheleva, D, Hajduch, M. Aurora kinases: structure, functions and their association with cancer. Biomedical Papers of the Medical Faculty of the University of Palacky, Olomouc, Czech Republic 2008;152:27–33.
Giet, R, Prigent, C. Aurora/Ipl1p-related kinases, a new oncogenic family of mitotic serine-threonine kinases. Journal of Cell Science 1999;112:3591–601.
Fu, J, Bian, M, Liu, J, Jiang, Q, Zhang, C. A single amino acid change converts Aurora-A into Aurora-B-like kinase in terms of partner specificity and cellular function. Proceedings of the National Academy of Sciences USA 2009;106:6939–44.
Kimura, M, Matsuda, Y, Eki, T, et al. Assignment of STK6 to human chromosome 20q13.2–<q13.3 and a pseudogene STK6P to 1q41–<q42. Cytogenetics and Cell Genetics 1997;79:201–3.
Berdnik, D, Knoblich, JA. Drosophila Aurora-A is required for centrosome maturation and actin-dependent asymmetric protein localization during mitosis. Current Biology 2002;12:640–7.
Hirota, T, Kunitoku, N, Sasayama, T, et al. Aurora-A and an interacting activator, the LIM protein Ajuba, are required for mitotic commitment in human cells. Cell 2003;114:585–98.
Andrews, PD, Knatko, E, Moore, WJ, Swedlow, JR. Mitotic mechanics: the auroras come into view. Current Opinion in Cell Biology 2003;15:672–83.
Gizatullin, F, Yao, Y, Kung, V, et al. The Aurora kinase inhibitor VX-680 induces endoreduplication and apoptosis preferentially in cells with compromised p53-dependent postmitotic checkpoint function. Cancer Research 2006;66:7668–77.
Kimura, M, Matsuda, Y, Yoshioka, T, Okano, Y.Cell cycle-dependent expression and centrosome localization of a third human aurora/Ipl1-related protein kinase, AIK3. Journal of Biological Chemistry 1999;274:7334–40.
Yang, SC, Huang, CH, Chen, NJ, Chou, CK, Lin, CH.Functional implication of human serine/threonine kinase, hAIK, in cell cycle progression. Journal of Biomedical Science 2000;7:484–93.
Roghi, C, Giet, R, Uzbekov, R, et al. The Xenopus protein kinase pEg2 associates with the centrosome in a cell cycle-dependent manner, binds to the spindle microtubules and is involved in bipolar mitotic spindle assembly. Journal of Cell Science 1998;111:557–72.
Walter, AO, Seghezzi, W, Korver, W, Sheung, J, Lees, E. The mitotic serine/threonine kinase Aurora2/AIK is regulated by phosphorylation and degradation. Oncogene 2000;19:4906–16.
Long, ZJ, Xu, J, Yan, M, et al. ZM 447439 inhibition of aurora kinase induces Hep2 cancer cell apoptosis in three-dimensional culture. Cell Cycle 2008;7:1473–9.
Marumoto, T, Honda, S, Hara, T, et al. Aurora-A kinase maintains the fidelity of early and late mitotic events in HeLa cells. Journal of Biological Chemistry 2003;278:51 786–95.
Dutertre, S, Cazales, M, Quaranta, M, et al. Phosphorylation of CDC25B by Aurora-A at the centrosome contributes to the G2-M transition. Journal of Cell Science 2004;117:2523–31.
Tsai, MY, Wiese, C, Cao, K, et al. A Ran signalling pathway mediated by the mitotic kinase Aurora A in spindle assembly. Nature Cell Biology 2003;5:242–8.
Eyers, PA, Erikson, E, Chen, LG, Maller, JL. A novel mechanism for activation of the protein kinase Aurora A. Current Biology 2003;13:691–7.
Garrett, S, Auer, K, Compton, DA, Kapoor, TM. hTPX2 is required for normal spindle morphology and centrosome integrity during vertebrate cell division. Current Biology 2002;12:2055–9.
Kunitoku, N, Sasayama, T, Marumoto, T, et al. CENP-A phosphorylation by Aurora-A in prophase is required for enrichment of Aurora-B at inner centromeres and for kinetochore function. Developmental Cell 2003;5:853–64.
Meraldi, P, Honda, R, Nigg, EA. Aurora-A overexpression reveals tetraploidization as a major route to centrosome amplification in p53-/- cells. EMBO Journal 2002;21:483–92.
Honda, K, Mihara, H, Kato, Y, et al. Degradation of human Aurora2 protein kinase by the anaphase-promoting complex-ubiquitin-proteasome pathway. Oncogene 2000;19:2812–19.
Hauf, S, Cole, RW, LaTerra, S, et al. The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint. Journal of Cell Biology 2003;161:281–94.
Tatsuka, M, Katayama, H, Ota, T, et al. Multinuclearity and increased ploidy caused by overexpression of the aurora- and Ipl1-like midbody-associated protein mitotic kinase in human cancer cells. Cancer Research 1998;58:4811–16.
Monier, K, Mouradian, S, Sullivan, KF. DNA methylation promotes Aurora-B-driven phosphorylation of histone H3 in chromosomal subdomains. Journal of Cell Science 2007;120:101–14.
Bolton, MA, Lan, W, Powers, SE, et al. Aurora B kinase exists in a complex with survivin and INCENP and its kinase activity is stimulated by survivin binding and phosphorylation. Molecular Biology of the Cell 2002;13:3064–77.
Bishop, JD, Schumacher, JM. Phosphorylation of the carboxyl terminus of inner centromere protein (INCENP) by the Aurora B Kinase stimulates Aurora B kinase activity. Journal of Biological Chemistry 2002;277:27 577–80.
Bourhis, E, Hymowitz, SG, Cochran, AG. The mitotic regulator Survivin binds as a monomer to its functional interactor Borealin. Journal of Biological Chemistry 2007;282:35 018–23.
Giet, R, Glover, DM.Drosophila aurora B kinase is required for histone H3 phosphorylation and condensin recruitment during chromosome condensation and to organize the central spindle during cytokinesis. Journal of Cell Biology 2001;152:669–82.
Kallio, MJ, McCleland, ML, Stukenberg, PT, Gorbsky, GJ. Inhibition of aurora B kinase blocks chromosome segregation, overrides the spindle checkpoint, and perturbs microtubule dynamics in mitosis. Current Biology 2002;12:900–5.
Fang, G. Checkpoint protein BubR1 acts synergistically with Mad2 to inhibit anaphase-promoting complex. Molecular Biology of the Cell 2002;13:755–66.
Keen, N, Taylor, S. Mitotic drivers–inhibitors of the Aurora B Kinase. Cancer and Metastasis Reviews 2009;28:185–95.
Li, X, Sakashita, G, Matsuzaki, H, et al. Direct association with inner centromere protein (INCENP) activates the novel chromosomal passenger protein, Aurora-C. Journal of Biological Chemistry 2004;279:47 201–11.
Katayama, H, Ota, T, Jisaki, F, et al. Mitotic kinase expression and colorectal cancer progression. Journal of the National Cancer Institute 1999;91:1160–2.
Sakakura, C, Hagiwara, A, Yasuoka, R, et al. Tumour-amplified kinase BTAK is amplified and overexpressed in gastric cancers with possible involvement in aneuploid formation. British Journal of Cancer 2001;84:824–31.
Goepfert, TM, Adigun, YE, Zhong, L, et al. Centrosome amplification and overexpression of aurora A are early events in rat mammary carcinogenesis. Cancer Research 2002;62:4115–22.
Zhou, H, Kuang, J, Zhong, L, et al. Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nature Genetics 1998;20:189–93.
Wang, X, Zhou, YX, Qiao, W, et al. Overexpression of aurora kinase A in mouse mammary epithelium induces genetic instability preceding mammary tumor formation. Oncogene 2006;25:7148–58.
Jeng, YM, Peng, SY, Lin, CY, Hsu, HC. Overexpression and amplification of Aurora-A in hepatocellular carcinoma. Clinical Cancer Research 2004;10:2065–71.
Abad, M, Ciudad, J, Rincon, MR, et al. DNA aneuploidy by flow cytometry is an independent prognostic factor in gastric cancer. Analytical Cellular Pathology 1998;16:223–31.
Sasaki, O, Kido, K, Nagahama, S. DNA ploidy, Ki-67 and p53 as indicators of lymph node metastasis in early gastric carcinoma. Analytical and Quantitative Cytology and Histology 1999;21:85–8.
Sturgis, CD, Caraway, NP, Johnston, DA, et al. Image analysis of papillary thyroid carcinoma fine-needle aspirates: significant association between aneuploidy and death from disease. Cancer 1999;87:155–60.
Pihan, GA, Purohit, A, Wallace, J, et al. Centrosome defects and genetic instability in malignant tumors. Cancer Research 1998;58:3974–85.
Pihan, GA, Purohit, A, Wallace, J, et al. Centrosome defects can account for cellular and genetic changes that characterize prostate cancer progression. Cancer Research 2001;61:2212–19.
Zhang, C, Fang, Z, Xiong, Y, et al. Copy number increase of aurora kinase A in colorectal cancers: a correlation with tumor progression. Acta Biochimica et Biophysica Sinica (Shanghai)2010;42:834–8.
Levrero, M, De Laurenzi, V, Costanzo, A, et al. The p53/p63/p73 family of transcription factors: overlapping and distinct functions. Journal of Cell Science 2000;113(10):1661–70.
Katayama, H, Sasai, K, Kawai, H, et al. Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53. Nature Genetics 2004;36:55–62.
Liu, Q, Kaneko, S, Yang, L, et al. Aurora-A abrogation of p53 DNA binding and transactivation activity by phosphorylation of serine 215. Journal of Biological Chemistry 2004;279:52 175–82.
Dar, AA, Zaika, A, Piazuelo, MB, et al. Frequent overexpression of Aurora Kinase A in upper gastrointestinal adenocarcinomas correlates with potent antiapoptotic functions. Cancer 2008;112:1688–98.
Khwaja, A. Akt is more than just a Bad kinase. Nature 1999;401:33–4.
Guan, Z, Wang, XR, Zhu, XF, et al. Aurora-A, a negative prognostic marker, increases migration and decreases radiosensitivity in cancer cells. Cancer Research 2007;67:10 436–44.
Ogawara, Y, Kishishita, S, Obata, T, et al. Akt enhances Mdm2-mediated ubiquitination and degradation of p53. Journal of Biological Chemistry 2002;277:21 843–50.
Dar, AA, Belkhiri, A, Ecsedy, J, Zaika, A, El-Rifai, W. Aurora kinase A inhibition leads to p73-dependent apoptosis in p53-deficient cancer cells. Cancer Research 2008;68:8998–9004.
Thottassery, JV, Westbrook, L, Someya, H, Parker, WB. c-Abl-independent p73 stabilization during gemcitabine- or 4’-thio-beta-D-arabinofuranosylcytosine-induced apoptosis in wild-type and p53-null colorectal cancer cells. Molecular Cancer Therapeutics 2006;5:400–10.
Ouchi, M, Fujiuchi, N, Sasai, K, et al. BRCA1 phosphorylation by Aurora-A in the regulation of G2 to M transition. Journal of Biological Chemistry 2004;279:19 643–8.
Kurai, M, Shiozawa, T, Shih, HC, et al. Expression of Aurora kinases A and B in normal, hyperplastic, and malignant human endometrium: Aurora B as a predictor for poor prognosis in endometrial carcinoma. Human Pathology 2005;36:1281–8.
Dar, AA, Belkhiri, A, El-Rifai, W. The aurora kinase A regulates GSK-3beta in gastric cancer cells. Oncogene 2009;28:866–75.
Hung, LY, Tseng, JT, Lee, YC, et al. Nuclear epidermal growth factor receptor (EGFR) interacts with signal transducer and activator of transcription 5 (STAT5) in activating Aurora-A gene expression. Nucleic Acids Research 2008;36:4337–51.
Biggins, S, Murray, AW. The budding yeast protein kinase Ipl1/Aurora allows the absence of tension to activate the spindle checkpoint. Genes and Development 2001;15:3118–29.
Ota, T, Suto, S, Katayama, H, et al. Increased mitotic phosphorylation of histone H3 attributable to AIM-1/Aurora-B overexpression contributes to chromosome number instability. Cancer Research 2002;62:5168–77.
Araki, K, Nozaki, K, Ueba, T, Tatsuka, M, Hashimoto, N. High expression of Aurora-B/Aurora and Ipll-like midbody-associated protein (AIM-1) in astrocytomas. Journal of Neurooncology 2004;67:53–64.
Barthel, H, Perumal, M, Latigo, J, et al. The uptake of 3’-deoxy-3’-[18F]fluorothymidine into L5178Y tumours in vivo is dependent on thymidine kinase 1 protein levels. European Journal of Nuclear Medicine and Molecular Imaging 2005;32:257–63.
Kanda, A, Kawai, H, Suto, S, et al. Aurora-B/AIM-1 kinase activity is involved in Ras-mediated cell transformation. Oncogene 2005;24:7266–72.
Pollard, JR, Mortimore, M.Discovery and development of aurora kinase inhibitors as anticancer agents. Journal of Medicinal Chemistry 2009;52:2629–51.
Ditchfield, C, Johnson, VL, Tighe, A, et al. Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores. Journal of Cell Biology 2003;161:267–80.
Girdler, F, Gascoigne, KE, Eyers, PA, et al. Validating Aurora B as an anti-cancer drug target. Journal of Cell Science 2006;119:3664–75.
Girdler, F, Sessa, F, Patercoli, S, et al. Molecular basis of drug resistance in aurora kinases. Chemical Biology 2008;15:552–62.
Yang, J, Ikezoe, T, Nishioka, C, et al. AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo. Blood 2007;110:2034–40.
Nair, JS, de Stanchina, E, Schwartz, GK. The topoisomerase I poison CPT-11 enhances the effect of the aurora B kinase inhibitor AZD1152 both in vitro and in vivo. Clinical Cancer Research 2009;15:2022–30.
Wilkinson, RW, Odedra, R, Heaton, SP, et al. AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis. Clinical Cancer Research 2007;13:P–8.
Libertini, S, Abagnale, A, Passaro, C, et al. AZD1152 negatively affects the growth of anaplastic thyroid carcinoma cells and enhances the effects of oncolytic virus dl922–947. Endocrine-Related Cancer 2011;18:129–41.
Boss, DS, Witteveen, PO, van der Sar, J, et al. Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors. Annals of Oncology 2011;22:431–7.
Harrington, EA, Bebbington, D, Moore, J, et al. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nature Medicine 2004;10:262–7.
Lin, YG, Immaneni, A, Merritt, WM, et al. Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth. Clinical Cancer Research 2008;14:5437–46.
Wan, XB, Long, ZJ, Yan, M, et al. Inhibition of Aurora-A suppresses epithelial-mesenchymal transition and invasion by downregulating MAPK in nasopharyngeal carcinoma cells. Carcinogenesis 2008;29:1930–7.
Lee, EC, Frolov, A, Li, R, Ayala, G, Greenberg, NM. Targeting Aurora kinases for the treatment of prostate cancer. Cancer Research 2006;66:4996–5002.
Huang, XF, Luo, SK, Xu, J, et al. Aurora kinase inhibitory VX-680 increases Bax/Bcl-2 ratio and induces apoptosis in Aurora-A-high acute myeloid leukemia. Blood 2008;111:2854–65.
Manfredi, MG, Ecsedy, JA, Meetze, KA, et al. Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase. Proceedings of the National Academy of Sciences USA 2007;104:4106–11.
Wunderlich, A, Fischer, M, Schlosshauer, T, et al. Evaluation of Aurora kinase inhibition as a new therapeutic strategy in anaplastic and poorly differentiated follicular thyroid cancer. Cancer Science 2011;102:762–8.
Hoar, K, Chakravarty, A, Rabino, C, et al. MLN8054, a small-molecule inhibitor of Aurora A, causes spindle pole and chromosome congression defects leading to aneuploidy. Molecular and Cellular Biology 2007;27:4513–25.
Dees, EC, Infante, JR, Cohen, RB, et al. Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology 2011;67:945–54.
Maris, JM, Morton, CL, Gorlick, R, et al. Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). Pediatric Blood and Cancer;55:26–34.
Gorgun, G, Calabrese, E, Hideshima, T, et al. A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. Blood 2010;115:5202–13.
Kelly, KR, Ecsedy, J, Medina, E, et al. The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukemia and significantly increases the efficacy of nilotinib. Journal of Cellular and Molecular Medicine 2011;15:2057–70.
Soncini, C, Carpinelli, P, Gianellini, L, et al. PHA-680632, a novel Aurora kinase inhibitor with potent antitumoral activity. Clinical Cancer Research 2006;12:4080–9.
Tao, Y, Zhang, P, Frascogna, V, et al. Enhancement of radiation response by inhibition of Aurora-A kinase using siRNA or a selective Aurora kinase inhibitor PHA680632 in p53-deficient cancer cells. British Journal of Cancer 2007;97:1664–72.
Carpinelli, P, Ceruti, R, Giorgini, ML, et al. PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer. Molecular Cancer Therapeutics 2007;6:3158–68.
Gontarewicz, A, Balabanov, S, Keller, G, et al. Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I. Blood 2008;111:4355–64.
Benten, D, Keller, G, Quaas, A, et al. Aurora kinase inhibitor PHA-739358 suppresses growth of hepatocellular carcinoma in vitro and in a xenograft mouse model. Neoplasia 2009;11:934–44.
Cohen, RB, Jones, SF, Aggarwal, C, et al. A Phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumors. Clinical Cancer Research 2009;15:6694–701.
Steeghs, N, Eskens, FA, Gelderblom, H, et al. Phase I pharmacokinetic and pharmacodynamic study of the aurora kinase inhibitor danusertib in patients with advanced or metastatic solid tumors. Journal of Clinical Oncology 2009;27:5094–101.
Walsby, E, Walsh, V, Pepper, C, Burnett, A, Mills, K. Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blasts. Haematologica 2008;93:662–9.
Zhang, L, Zhang, S.ZM447439, the Aurora kinase B inhibitor, suppresses the growth of cervical cancer SiHa cells and enhances the chemosensitivity to cisplatin. Journal of Obstetric and Gynaecological Research 2011;37:591–600.
Crispi, S, Fagliarone, C, Biroccio, A, et al. Antiproliferative effect of Aurora kinase targeting in mesothelioma. Lung Cancer 2010;70:271–9.
Georgieva, I, Koychev, D, Wang, Y, et al. ZM447439, a novel promising aurora kinase inhibitor, provokes antiproliferative and proapoptotic effects alone and in combination with bio- and chemotherapeutic agents in gastroenteropancreatic neuroendocrine tumor cell lines. Neuroendocrinology 2010;91:121–30.
Li, M, Jung, A, Ganswindt, U, et al. Aurora kinase inhibitor ZM447439 induces apoptosis via mitochondrial pathways. Biochemical Pharmacology 2010;79:122–9.
Gadea, BB, Ruderman, JV. Aurora kinase inhibitor ZM447439 blocks chromosome-induced spindle assembly, the completion of chromosome condensation, and the establishment of the spindle integrity checkpoint in Xenopus egg extracts. Molecular Biology of the Cell 2005;16:1305–18.
Emanuel, S, Rugg, CA, Gruninger, RH, et al. The in vitro and in vivo effects of JNJ-7706621: a dual inhibitor of cyclin-dependent kinases and aurora kinases. Cancer Research 2005;65:9038–46.
Godl, K, Gruss, OJ, Eickhoff, J, et al. Proteomic characterization of the angiogenesis inhibitor SU6668 reveals multiple impacts on cellular kinase signaling. Cancer Research 2005;65:6919–26.
Laird, AD, Vajkoczy, P, Shawver, LK, et al. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Research 2000;60:4152–60.
Chan, F, Sun, C, Perumal, M, et al. Mechanism of action of the Aurora kinase inhibitor CCT129202 and in vivo quantification of biological activity. Molecular Cancer Therapeutics 2007;6:3147–57.
Howard, S, Berdini, V, Boulstridge, JA, et al. Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity. Journal of Medicinal Chemistry 2009;52:379–88.
Curry, J, Angove, H, Fazal, L, et al. Aurora B kinase inhibition in mitosis: strategies for optimising the use of aurora kinase inhibitors such as AT9283. Cell Cycle 2009;8:1921–9.
Dawson, MA, Curry, JE, Barber, K, et al. AT9283, a potent inhibitor of the Aurora kinases and Jak2, has therapeutic potential in myeloproliferative disorders. British Journal of Haematology 2010;150:46–57.
Tanaka, R, Squires, MS, Kimura, S, et al. Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL-positive leukemic cells. Blood 2010;116:2089–95.
Kristeleit, R, Arkenau, H, Olmos, D, et al. A Phase I study of AT9283, an aurora kinase inhibitor, in patients with refractory solid tumors. Journal of Clinical Oncology 2009;27(15S).
Arbitrario, JP, Belmont, BJ, Evanchik, MJ, et al. SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo. Cancer Chemotherapy and Pharmacology 2010;65:707–17.
Griffiths, G, Sorrell, D, Duckmanton, A, et al. Anti-tumor activity of CYC116, a novel small molecule inhibitor of Aurora kinases and VEGFR2. AACR Annual Meeting 12–16 April 2008, San Diego, CA.
Jani, JP, Arcari, J, Bernardo, V, et al. PF-03814735, an orally bioavailable small molecule aurora kinase inhibitor for cancer therapy. Molecular Cancer Therapeutics 2010;9:883–94.
Cancel
Confirm
×